This thesis focuses on how physical and biological factors influence the outcome of exposures to γ/X-rays. That the dose rate changes during real life exposure scenarios is well-known, but radiobiological data from exposures performed at increasing or decreasing dose rates is lacking. In paper I, it was found that an exposure where the dose rate decreases exponentially induces significantly higher levels of micronuclei in TK6 cells than exposures at an increasing or constant dose rate. Paper II describes the construction and validation of novel exposure equipment used to further study this “decreasing dose rate effect”, which is described in paper III. In paper I we also observed a radioprotective effect when cells were exposed on ice. This “temperature effect” (TE) has been known for decades but it is still not fully understood how hypothermia acts in a radioprotective manner. This was investigated in paper IV, where a multiparametric approach was used to investigate the underlying mechanisms. In paper V the aim was to investigate the role of biomarkers and clinical parameters as possible risk factors for late adverse effects to radiotherapy (RT). This was studied in a rare cohort of head-and-neck cancer patients that developed mandibular osteoradionecrosis (ORN) as a severe late adverse effect of RT. Biomarker measurements and clinical factors were then subjected to multivariate analysis in order to identify ORN risk factors. The results suggest that the patient’s oxidative stress response is an important factor in ORN pathogenesis, and support the current view that patient-related factors constitute the largest source of variation seen in the frequency of late adverse effects to RT. In summary, this thesis provides new and important insights into the roles of biological and physical factors in determining the consequences of γ/X-ray exposures. / <p>At the time of the doctoral defense, the following papers were unpublished and had a status as follows: Paper 3: Submitted. Paper 5: Manuscript.</p>

5 à 15% des 175 000 patients traités par radiothérapie (RT) chaque année sont exposés à une toxicité considérée comme « inhabituelle » pouvant entraîner des séquelles parfois graves. Les techniques innovantes de photonthérapie apportent une solution balistique pertinente mais inappropriée pour certaines tumeurs ou certains patients. Deux approches permettent d'entrevoir des solutions à ces situations. 1- Contribution au développement de l'hadronthérapie par ions carbone : Ces particules possèdent une masse et une charge qui leur confèrent un avantage balistique et biologique particulièrement intéressant. Le caractère rare des tumeurs éligibles et le très faible nombre de centres n'ont pas permis, ou justifié, à ce jour la réalisation d'études comparatives randomisées afin d'en évaluer le service rendu. Via le projet FP7 ULICE, nous avons intégré et animé plusieurs groupes à l'échelle nationale et internationale. Nous avons directement produit des procédures unifiées en terme d'immobilisation, de recueil des données élémentaires, de structuration protocolaire et de transformation des données en métadonnées échangeables. Nous avons proposé des concepts originaux permettant de décrire la dose prescrite et les volumes d'intérêt, au-delà du concept réducteur d'EBR. 2- Un nouveau biomarqueur de radiosensibilité individuelle (RSI). L'identification des patients les plus à risque de développer les réactions les plus sévères reste un enjeu majeur. Aucun test de RSI ne s'impose comme gold standard. A partir de primocultures fibroblastiques issues de patients ayant présenté un profil de toxicité inhabituel à la RT, le taux de cassures double brins résiduelles à 24h estimé par immunofluorescence indirecte (marqueur γH2AX) a permis de définir 3 groupes de RSI. Toutefois ce seul marqueur n'est pas assez robuste. Le délai de transit cyto-nucléaire de la protéine ATM semble affiner notre classification. Un nouveau modèle mécanistique a ainsi pu être développé / 5 to 15% of the 175,000 patients treated with radiation therapy (RT) annually are exposed to toxicity considered "unusual" that can lead to serious sequelae. Innovative photon RT techniques provide relevant but inappropriate ballistic solution for certain tumors or certain patients. Two approaches guide solutions to these situations.1- Contribution to the development of carbon ion RT. These particles possess a mass and a charge that give them particularly interesting ballistics and biological properties. The rarity of eligible tumors and the low care offer have failed conducting randomized controlled trials to evaluate its cost-effectiveness. Throughout the FP7-ULICE project, we directly produced standard operating procedures in terms of basic data collection, protocol structuring and processing of metadata. We proposed original concepts to describe and report the dose and volume of interest, beyond the restricted concept of RBE. 2- A novel biomarker of individual radiosensitivity (IRS). The identification of the patients the most at risk of developing the most severe reactions remains a major challenge. There is no gold standard in the field of IRS assays.From fibroblasts primocultures sampled from patients with an unusual toxicity, the number of residual DNA double-stand breaks 24h after radiation and estimated by indirect immunofluorescence (marker γH2AX) allows to identify three groups of IRS. However this single marker is not robust enough. The delay of ATM nucleoshuttling appears to refine our classification. A new mechanistic model has been developed